Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant.

ABSTRACT:

Aims

High dose melphalan (HDM) and autologous stem cell transplant (ASCT) is standard of care for multiple myeloma (MM), but there is significant variability in melphalan exposure (area under the plasma drug concentration-time curve, AUC) when using body surface area-based dosing. Our aim was to establish a method of pharmacokinetic (PK) testing for real-time melphalan dose adjustments.

Methods

We performed a prospective PK study of melphalan 140 or 200 mg/m² in MM patients undergoing ASCT. Twenty MM patients were administered HDM on days -2 and - 1, with PK sampling at 8-10 time points. PK testing was performed on day -2 in all patients, and on day -1 in 5 patients.

Results

Less than 20% interpatient variation in the day -2 and - 1 AUC was observed. The da

SUBMITTER: Sweiss K 

PROVIDER: S-EPMC7576633 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature